FDA clears C2N Diagnostics' early Alzheimer's assessment test

C2N Diagnostics received FDA clearance for its PrecivityAD2 blood test, the first Alzheimer's assessment approved for patients as young as 40, aiding earlier detection of amyloid pathology linked to Alzheimer's disease. The test supports clinical evaluation but is not a standalone diagnostic. This positions C2N competitively alongside Roche in a rapidly growing market anticipated to reach $33bn by 2033.

This Wire brief sits within Fusion42's coverage of Diagnostics.